The Experience of Inhaled COVID-19 Vaccination among First-line Medical Staff in Epidemic Prevention Aged≥18 Years in Guiyang City: a Qualitative Study
1. Department of Preventive Health, Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550002, China 2. Dean's Office of Guizhou Nursing Vactional College, Guiyang 550004, China 3. Nursing Department, Guizhou Provincial People's Hospital, Guiyang 550001, China 4. School of Nursing, Guizhou University of Traditional Chinese Medicine, Guiyang 550001, China 5. Emergency Department, Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550002, China
YU Na,BAI Xiaoling,PANG Jin, et al. The Experience of Inhaled COVID-19 Vaccination among First-line Medical Staff in Epidemic Prevention Aged≥18 Years in Guiyang City: a Qualitative Study[J]. Chinese General Practice, 2023, 26(36): 4575-4580. DOI: 10.12114/j.issn.1007-9572.2023.0176.
余娜,柏晓玲,逄锦等. 贵阳市≥18岁抗疫一线人员对吸入用新型冠状病毒疫苗接种体验的质性研究[J]. 中国全科医学, 2023, 26(36): 4575-4580. DOI: 10.12114/j.issn.1007-9572.2023.0176.
TUKHVATULINA I, GORDEYCHUKI V, DOLZHIKOVAI V,et al. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human Primates[J]. Emerg Microbes Infect,2022,11(1):2229-2247. DOI:10.1080/22221751.2022.2119169.
[4]
MALLAHN, PARDO-SECOJ, LÓPEZ-PÉREZL R,et al. Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in Spain[J]. Environ Res,2022,215(Pt 2):114252. DOI:10.1016/j.envres.2022.114252.
LIJ X, WUS P, GUOX L,et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults:a randomised,open-label,single-centre trial[J]. Lancet Respir Med,2022,10(8):739-748. DOI:10.1016/S2213-2600(22)00087-X.
WUS P, HUANGJ Y, ZHANGZ,et al. Safety,tolerability,and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults:preliminary report of an open-label and randomised phase 1 clinical trial[J]. Lancet Infect Dis,2021,21(12):1654-1664. DOI:10.1016/S1473-3099(21)00396-0.